Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
acute myeloid leukemia (AML)
Research
Amphista's targeted glue sticks the landing in early AML test
Amphista has reported preclinical leukemia data on its protein degrader, positioning the biotech to target a 2026 start date for a phase 1 trial.
Nick Paul Taylor
Dec 8, 2025 7:40am
TScan lays off 30% of workforce, halts solid tumor TCR trial
Nov 3, 2025 8:25am
Takeda drops AZ-partnered neurological program after ph. 2 fail
Oct 30, 2025 9:25am
Ipsen inks €1B buyout of French biotech ImCheck
Oct 22, 2025 10:33am
Schrödinger abandons CDC7 inhibitor linked to 2 patient deaths
Aug 14, 2025 8:23am
Sellas’ AML asset tied to 50% response rate in certain patients
Jul 15, 2025 10:34am
